An observational study on a cohort of 70,027 new insulin users in France found no differences in risk at median follow-up <3 years for bladder, breast, colorectal, head and neck, liver, lung and kidney cancer between new users of insulin glargine and other basal insulins, when excluding the first year of use and defining exposure as ever-use or cumulative dose [40]. Here, INS is linked to kidney cancer.